Brief: Biocryst Presents New Clinical Data And Real-World Evidence Demonstrating Impact Of Hae Portfolio At The 2026 European Academy Of Allergy And Clinical Immunology Annual Meeting
12/06/2026 12:03
BRIEF-Biocryst Presents New Clinical Data And Real-World Evidence Demonstrating Impact Of Hae Portfolio At The 2026 European Academy Of Allergy And Clinical Immunology Annual Meeting June 12 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O:
BIOCRYST PRESENTS NEW CLINICAL DATA AND REAL-WORLD EVIDENCE DEMONSTRATING IMPACT OF HAE PORTFOLIO AT THE 2026 EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY ANNUAL MEETING
Source text: ID:nGNX2RMPRr
Further company coverage: BCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026